BBLG Quote, Financials, Valuation and Earnings

Becton, Dickinson & Co. has a net margin of -- compared to Bone Biologics Corp.'s net margin of 8.37%. Bone Biologics Corp.'s return on equity of -86.54% beat Becton, Dickinson & Co.'s return on equity of 6.6%.

Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 1208.82%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 4.33%. Given that Bone Biologics Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Bone Biologics Corp. is more attractive than Becton, Dickinson & Co..

Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.828%.

Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton, Dickinson & Co. offers a yield of 2.12% to investors and pays a quarterly dividend of $1.05 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bone Biologics Corp. quarterly revenues are --, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. Bone Biologics Corp.'s net income of -$666.7K is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while Becton, Dickinson & Co.'s PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus 2.59x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Bone Biologics Corp.'s net margin of -255.85%. Bone Biologics Corp.'s return on equity of -86.54% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 1208.82%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Bone Biologics Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Bone Biologics Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Bone Biologics Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Bone Biologics Corp.'s net income of -$666.7K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Bone Biologics Corp.'s net margin of --. Bone Biologics Corp.'s return on equity of -86.54% beat Palatin Technologies's return on equity of --.

Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 1208.82%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Bone Biologics Corp., analysts believe Palatin Technologies is more attractive than Bone Biologics Corp..

Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Bone Biologics Corp. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Bone Biologics Corp.'s net income of -$666.7K is higher than Palatin Technologies's net income of --. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Bone Biologics Corp.'s net margin of --. Bone Biologics Corp.'s return on equity of -86.54% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 1208.82%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Bone Biologics Corp., analysts believe Theriva Biologics, Inc. is more attractive than Bone Biologics Corp..

Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Bone Biologics Corp. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Bone Biologics Corp.'s net income of -$666.7K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.